Investor Day IB FINAL
Investor Day IB FINAL
Investor Day IB FINAL
Key messages
11.7
(51%)
(36%)
7.4
9M07
9M09
225
(44%)
23.1 126
(30%)
16.1
1Q08
1
3Q09
1Q08
3Q09
Total assets excludes CHF 149 billion in 1Q08 and CHF 42 billion in 3Q09 of Group-related items
Franchise strengths
Attracting talent to the IB
FICC Equities IBD
200 FICC hires YTD Key hires1 115 new MDs and EDs 64% joined in last 3 months
167 Equities hires YTD 76 new MDs and EDs 58% joined in last 3 months
67 IBD hires YTD 31 new MDs and EDs 87% joined in last 3 months
Advisory Resilient positioning FX #2 globally 15% market share2 Cash Equities Top 3 globally 11% market share3 Top 4 globally 6.5% market share in 20094 ECM Top 3 global firm in 20095
Funding: +0.6
(CHF billion)
CLE: +1.3
Competitors building aggressively Regulatory considerations Talent retention and acquisition Introduction of FINMA leverage ratio
Regulatory changes
Key messages
Provider of all products, in all markets, chasing market share that is focused and disciplined
9
% of total
1.62
1.39 155
40 11 7 25 15 1
2008
Assets ex-PRVs
Indexed RoA (normalized revenues1 / average assets ex-PRVs and ex-residual risk positions, 2005 = 100)
2007 to 2009 total IB income normalized for losses. 2009 normalized for funding. Refer to slide 5 for details on normalization
Target
9M09
Sustainable profits
High
11
Key messages
12
Restructured FICC
Restructured, refocused and delivering better performance with fewer resources
FICC permanent personnel1
(FTEs) 3,000 2,500 2,000 1,500 1,000 500 0
(36%)
> 2.0
9M09
1.2 1.0
(64%)
Target quarter
Credit
FX & MM
1 2
Excludes residual risk positions and the assets and personnel related to them Refer to slide 5 for details on normalization
13
Execution
Agency and flow-based trading Add sales capabilities Rebuild client coverage Onshore emerging markets platforms Agency, flow-based and selected proprietary trading Add sales capabilities
FX&MM
Expand bespoke product offering Across products Leverage WM flow across products Enhance current direct execution platforms to broader products set Unified Quants team Structured product offering and solutions Increase automation of execution platforms
with a target quarterly run rate of > CHF 2 billion over the medium term
14
Market-leading FX franchise Industry recognized platform Experienced and talented team Client strength and support
Market opportunity
Increased flow to WM, corporate and institutional clients Customized solutions
Integrate execution platforms between Rates & FX
... which together are targeted to constitute over 50% of our FICC revenues
15
Credit revenues in 2009 running higher than pre-crisis run rate Lean staff structure Existing platforms ready to be leveraged New management team in place
Market opportunity
Deep market for flow products Demand for tailored solutions Positioning for recovery in IG acquisition financing and refinancing in HY markets
Add & rebuild selected product capabilities
Market opportunity
Rebuild and enhance LatAm presence
Execution
Enhance intermediaries platform Focus on efficient balance sheet usage Expand product solution capabilities for clients
Return to full research coverage Expand and further automate direct execution
Optimize current direct execution platforms to broaden product set Leverage WM flow including for derivatives OTC products moving on exchange
with a target quarterly run rate of > CHF 1.75 billion over the medium-term
18
Execution
Innovative and quick-to-market solutions Target capital raising, derivatives and securities products
Leverage existing senior IBD relationships Increase cross-product awareness / education Innovative and quick-to-market solutions
Leverage strengths to deliver a target quarterly run rate > CHF 1 billion
1 2 DCM Debt Capital Markets ECM Equity Capital Markets
19
Key messages
20
~20.0
Revenues / PBT
IBD Equities FICC Equities IBD
12.9
IBD
~6.0
3.3
Norm. 9M09
Expenses
9.6
Medium-term expectations
9M09 numbers annualized to show the bridge from an annual number to a full year medium-term goal. Annualized figures do not constitute estimates of the actual full-year results. Refer to slide 5 for details on normalization.
21
Key messages
22
Disclaimer
This presentation and the information contained herein is provided solely for information purposes, and is not to be construed as a solicitation of an offer to buy or sell any securities or other financial instruments in Switzerland, the United States or any other jurisdiction. No investment decision relating to securities of or relating to UBS AG or its affiliates should be made on the basis of this document. No representation or warranty is made or implied concerning, and UBS assumes no responsibility for, the accuracy, completeness, reliability or comparability of the information contained herein relating to third parties, which is based solely on public available information. UBS undertakes no obligation to update the information contained herein.
23